01951 JXR
- 2.800
- -0.030-1.06%
JXR News
錦欣生殖：2023年報
Is Now The Time To Look At Buying Jinxin Fertility Group Limited (HKG:1951)?
Jinxin Fertility Group Limited (HKG:1951), is not the largest company out there, but it saw significant share price movement during recent months on the SEHK, rising to highs of HK$2.84 and falli
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Changes in Hong Kong stocks | Jinxin Reproduction (01951) rose by more than 6%, and assisted reproduction was included in health insurance companies in many places to expand the assisted reproduction market in Southeast Asia
Jinxin Reproduction (01951) rose more than 6%. As of press release, it rose 6.17% to HK$2.58, with a turnover of HK$29.36,500.
[Hong Kong Stock Connect] Jinxin Reproduction (01951) rose 5.76%, Citi says its valuation is still attractive
Jinwu Financial News | Jinxin Reproduction (01951) stock price fluctuated and rose in early trading. As of press release, it had risen 5.76% to HK$2.57. According to the news, on April 1, Jinxin Reproductive Medical Group Co., Ltd. announced the signing of an equity investment agreement with PT Morula Indonesia. Jinxin Fertility said that after the investment is completed, Jinxin Fertility will become Morula's largest strategic investor. At the same time, the two sides will reach strategic cooperation, achieve resource integration, and work together to develop the assisted reproduction industry market in Indonesia and Southeast Asia. Citi released a research report saying that it will maintain Jinxin Reproduction's “buy” rating and consider
Jinxin Reproduction (01951.HK) and Indonesia's Morula reached an equity strategic investment cooperation to expand the assisted reproduction market in Southeast Asia
On April 1, 2024, Jinxin Reproductive Medicine Group Co., Ltd. (01951.HK) announced the signing of an equity investment agreement with Indonesia's PT Morula Indonesia (“Morula”). After the investment is completed, Jinxin Fertility will become Morula's largest strategic investor. At the same time, the two sides will reach strategic cooperation, achieve resource integration, and jointly explore the assisted reproduction industry market in Indonesia and Southeast Asia. The population of Southeast Asia is huge and continues to grow. At the same time, with economic development, residents' consumption capacity is also increasing, and the assisted reproduction industry has great potential for growth.
Open Source Securities: Maintaining Jinxin Reproduction's (01951) “Buy” rating, Shenzhen's new hospital is expected to be put into operation
Open Source Securities estimates that Jinxin Reproduction (01951)'s net profit for 2024-26 will be $3.87/46,538 million yuan.
JXR To Go Ex-Dividend On June 27th, 2024 With 0.0595 HKD Dividend Per Share
March 30th - $JXR(01951.HK)$ is trading ex-dividend on June 27th, 2024. Shareholders of record on June 28th, 2024 will receive 0.0595 HKD dividend per share on July 25th, 2024. The ex-dividend dat
Jinxin Fertility Logs 185% Profit Surge in 2023 as Revenue Rises 18%
Jinxin Fertility Group (HKG:1951) recorded a 184.6% rise in attributable profit for the year ended Dec. 31, 2023, to 344.7 million yuan from 121.1 million yuan in 2022, a filing posted on the Hong Kon
Understand the 2023 annual results highlights of Jinxin Reproduction (01951.HK) in one picture
On March 27, Jinxin Reproduction (01951.HK) announced the results for the year ended December 31, 2023. We will take you to understand the specific results in a chart.
Jinxin Reproduction (1951.HK): Remarkable results after the epidemic, with both high growth and certainty, the right time to invest
In 2023, the birth rate of China's population continued to decline and experienced negative population growth for the first time. Against this backdrop, “Jinxin Reproduction”, the first stock of assisted reproduction, announced financial results for the fiscal year 2023, achieving operating income of 2.79 billion yuan, an increase of 18% over the previous year. Its net profit and adjusted net profit reached 350 million yuan and 470 million respectively, achieving significant increases of 194% and 72% respectively compared to 2022, and even surpassed pre-pandemic levels. At the same time, the company also provided a cash dividend of about HK$164 million, and the dividend payment rate reached 43%.
Jinxin Reproduction (01951.HK) net profit of about 347 million yuan in 2023 increased by 194.2% year-on-year
Gelonghui, March 27 | Jinxin Reproduction (01951.HK) announced that for the year ended December 31, 2023, the Group's revenue was approximately RMB 2,789 million, an increase of 18.0% over the previous year. Net profit was approximately RMB 347 million, an increase of 194.2% over the previous year. Basic earnings per share was RMB 0.13. The adjusted basic earnings per non-IFRS share for the year ended 31 December 2023 (4) was RMB 0.18. The Board recommended a final dividend of HK5.95 cents per share for the year ended 31 December 2023 (up to 20
Jinxin Reproduction (01951) will pay a final dividend of HK$0.0595 per share on July 25
Jinxin Reproduction (01951) announced that the company will pay a final dividend of 0 per share on July 25, 2024...
JXR: ANNOUNCEMENT OF THE RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Jinxin Fertility issued 36.7922 million shares under the share award program
Jinxin Reproduction (01951) announced that the company will issue 36.7922 million shares under the 2022 Restricted Share Award Program on March 22, 2024.
Jinxin Reproduction (01951) issued 36.7922 million shares under the share award program
Jinxin Reproduction (01951) issued an announcement. The company announced on March 22, 2024, based on restricted shares in 2022...
[Yingxi Shares] Jinxin Reproduction (01951) rose 3.56%. Net profit is expected to increase by no less than 192% last year
Jinwu Financial News | Jinxin Reproduction (01951) rose in early trading. As of press release, it rose 3.56% to HK$2.62, with a turnover of HK$12.563,800. The company is pleased to announce that net profit and adjusted profit for the year ended December 31, 2023 will increase by no less than 192% and 71%, respectively, compared with the same period in 2022. According to the announcement, the increase was mainly due to the overall recovery and growth of the Group's assisted reproduction medical institutions after the end of the epidemic, including an increase in the number of patients consulted and in vitro fertilization (IVF) treatment cycles; and the optimization and enhancement of the operating efficiency of the Group and its medical institutions.
Jinxin Reproduction (01951) is pleased. Annual net profit and adjusted net profit are expected to increase by no less than 192% and 71% year-on-year respectively
Jinxin Reproduction (01951) issued an announcement expecting the Group's net profit and adjusted net profit for the 2023 fiscal year (non-international financial...
錦欣生殖：正面盈利預告
There Are Reasons To Feel Uneasy About Jinxin Fertility Group's (HKG:1951) Returns On Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Amongst other things, we'll want to see two things; firstly,
Analysis
Price Target
No Data
